· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2022 / N 2 Неалкогольная жировая болезнь печени как предиктор неблагоприятного течения COVID-19 С.А. Алиева, И.Г. Никитин Список литературы/References 1. World Health Organization. Coronavirus disease (COVID-19) pandemic. Accessed 2022 Jul 27. https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. DOI: 10.1001/jama.2020.1585 3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46(6):1294-1297. DOI: 10.1007/s00134-020-05991-x 4. Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020;30(5):688-699. [Bubnova MG, Aronov DM. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya. 2020;30(5):688-699. (In Russ.).] DOI: 10.18093/0869-0189-2020-30-5-688-699 5. Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease – what we know on 1st May 2020. Alimentary Pharmacology & Therapeutics. 2020;52(2):267-275. DOI: 10.1111/apt15813 6. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impacts on 1590 patients with COVID-19 in China: a national analysis. The European Respiratory Journal. 2020;55(5):2000547. DOI: 10.1183/139930003.01227-2020 7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine. 2020;382(18):1708-1720. DOI: 10.1056/NEJMoa2002032 8. Guan WJ, Liang WH, He JX, Zhang NSh. Comorbidity and COVID-19 in China: a national analisys. European Respiratory Journal. 2020;56(8):200546. DOI:10.1183/139930003.01224-2020 9. Zahed M, Yousef M, Abounoori M, Malekan M, Tajik F, Heydari K, Mortazavi P, Ghahramani S, Ghzaeian M, Sheydaee F, Nasirzadeh A, Alizadeh-Navaei R. The interrelationship between liver function test and the coronavirus disease 2019: a systematic review and meta-analysis. Iranian Journal of Medical Sciences. 2021;46(4):237-255. DOI: 10.30476/ijms.2021.87555.1793 10. Yoo HW, Jin HY, Yon DK, Effenberger M, Shin YH, Kim SY, Yang JM, Kim MS, Koyanagi A, Jacob L, Smith L, Yoo IK, Shin JI, Lee SW. Non-alcoholic fatty liver disease and COVID-19 susceptibility and outcomes: a Korean nationwide cohort. Journal of Korean Medical Science. 2021;36(41):e291. DOI: 10.3346/jkms.2021.36.e291 11. Qi X, Liu S, Jiang Z, Gu Y, Zhang G, Shao C, Yue H, Chen Z, Ma B, Liu D, Zhang L, Wang J, Xu D, Lei J, Li X, Huang H, Wang Y, Liu H, Yang J, Pan H, Liu W, Wang W, Li F, Zou S, Zhang H, Dong J. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. Journal of Hepatology. 2020;73(2):455-458. DOI: 10.1016/j.jhep.2020.04.010 12. Wong YJ, Tan M, Zheng Q, Li JW, Kumar R, Fock KW, Teo EK, Anga TL. A systematic review and meta-analysis of the COVID-19 associated liver injury. Annals of Hepatology. 2020;19(6):627-634. DOI: 10.1016/j.aohep.2020.08.064 13. Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NU, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. Journal of Hepatology. 2020;73(3):705-708. DOI: 10.1016/j.jhep.2020.05.013 14. Huang С, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia X, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. DOI: 10.1016/s0140-6736(20).30183-5 15. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742-1752. DOI: 10.1111/all.14309 16. Зыкина Е.Ю., Симонова Ж.Г. Особенности состояния ферментов печени и клинического статуса больных новой коронавирусной инфекцией (COVID-19) на фоне избыточной массы тела и ожирения. Экспериментальная и клиническая гастроэнтерология. 2021;7(191):6-11 [Zykina EYu, Simonova ZhG. Peculiarities of liver enzymes and clinical status of patients with novel coronavirus infection (COVID-19) against background of excess body weight and obesity. Experimental and Clinical Gastroenterology. 2021;7(191): 6-11 (In Russ.).] DOI: 10.31146/1682-8658-ecg-191-7-6-11 17. Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Reports. Innovation in Hepatology. 2019;1(1):30-43. DOI: 10.1016/j.jhepr.2019.02.004 18. Biquard L, Valla D, Rautou PE. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. Journal of Hepatology. 2020;73(3):717-718. DOI: 10/1016/j/jhep.2020.04.035 19. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. DOI: 10/1016/s0140-6736(20)30211-7 20. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. Journal of Hepatology. 2020;73(2):451-453. DOI: 10.1016/j.jhep.2020.03.044 21. Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun KF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545-1547. DOI: 10.1136/gutjnl-2020-321611 22. Herta T, Berg T. COVID-19 and the liver – lessons learned. Liver International. 2021;41(Suppl 1):1-8. DOI: 10.1111/liv.14854 23. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. The Lancet. Gastroenterology & Hepatology. 2020;5(5):428-430. DOI: 10.1016/S2468-1253(20)30057-1 24. Bramante C, Tignanelli ChJ, Dutta N, Jones E, Tamariz L, Clark JM, Usher M, Metlon-Meaux G, Ikramuddin S. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv. 2020 Sep 2;2020.09.01.20185850. DOI: 10.1101/2020.09.01.20185850. Preprint. 25. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, Yee NTS, Liu C, Nerurkar SN, Kai JCY, Teng MLP, Li X, Zeng H, Borghi JA, Henry L, Cheung R, Nguyen MH. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. Journal of Medical Virology. 2021;93(3):1449-1458. DOI: 10.1002/jmv.26424 26. Никитин И.Г., Ильченко Л.Ю., Федоров И.Г., Тотолян Г.Г. Поражение печени при COVID-19: два клинических наблюдения. Альманах клинической медицины. 2020;48(6):412-421. [Nikitin IG, Ilchenko LY, Fyodorov IG, Totolyan GG. Liver injury in COVID-19: two clinical cases. Almanac of Clinical Medicine. 2020;48(6):412-421 (In Russ.).] DOI: 10.18786/2072-0505-2020-48-053 27. Hanley B, Lucas S, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. Journal of Clinician Pathology. 2020;73(5):239-242. DOI: 10.1136/jclinpath-2020-206522 28. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology. 2013;19(41):6969-6978. DOI: 10.3748/wjg.v.19i41.6969 29. Mitsuyoshi H, Yasui K, Hara T, Taketani H, Ishiba H, Okajima A, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Minami M, Itoh Y. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease. Hepatology Research. 2017;47(13):1459-1468. DOI: 10.1111/hepr.12883 30. Farag NS, Breitinger U, Breitinger HG, El Azizi MA. Viroporins and inflammasomes: a key to understand virus-induced inflammation. The International Journal of the Biochemistry & Cell Biology. 2020;122:105738. DOI: 10.1016/j.biocel.2020.105738 31. Grimaudo S, Amodio E, Pipitone RM, Maida CM, Pizzo S, Prestileo T, Tramuto F, Sardina D, Vitale F, Casuccio A, Craxì A. PNPLA3 and TLL-1 polymorphisms as potential predictors of disease severity in patients with COVID-19. Frontiers in Cell and Developmental Biology. 2021;9:627914. DOI: 10.3389/fcell.2021.627914 32. Amodio E, Pipitone RM, Grimaudo S, Immordino P, Maida CM, Prestileo T, Restivo V, Tramuto F, Vitale F, Craxì A, Casuccio A. SARS-CoV-2 viral load, IFNλ polymorphisms and the course of COVID-19: an observational study. Journal of Clinical Medicine. 2020;9(10):3315. DOI: 10.3390/jcm9103315    [ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]